Moreover, Strides Pharma’s ambitious plans to launch approximately 60 new products in the US over the next three years further underscore its commitment to portfolio diversification and expansion. This forward-looking approach aligns with the company’s overarching objective of bolstering its market presence and addressing evolving healthcare needs. - Newsx
Grasim Industries, Sun Pharma, Power Grid Corporation, Paytm, Nykaa, Ashoka Buildcon, Dhanlaxmi Bank, GE Power India, Gland Pharma, GMM Pfaudler, HEG, Jubilant FoodWorks, New India Assurance Company, and Unichem Laboratories will announce their March quarter earnings on May 22.
In April 2022, FDA released a proposed draft guidance (FDA Dock. No. 2022-D-0108) involving pH adjusters in drug development relating to ophthalmic, parenteral, or otic drug products.
Strides Pharma gets USFDA nod for its drug to treat elevated phosphorous levels financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Strides Pharma Global receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.